Search results
Showing 3651 to 3700 of 8238 results
See a complete list of all our guidance and quality standards currently open for consultation
The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.
A joint NICE and NHS England meeting can help to ensure you're ready for NHS patient access and subsequent NICE appraisal
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the cost comparison appraisal
Our forward view highlights the topics we will prioritise in the coming year.
Home What NICE does Our research work HTA Lab...
Past technology appraisal appeals and decisions
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
Our indicators measure outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
Our quality standards set out priority areas for quality improvement in health, public health and social care.
A timeline showing where in the NICE evaluation process companies will be charged.
A step-by-step summary about how we develop our technology appraisal guidance.
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.
This guidance evaluates digital technologies, diagnostics and medical devices (including artificial intelligence).
Biographies for all current members of the diagnostics advisory committee.
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
How to register with us as a diagnostic technologies stakeholder.
How to register with us as a medical technologies stakeholder.
People and communities - putting you at the heart of our work
NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Biographies and registered interests for members of the Technology Appraisal Committee A
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)
NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .
Contrast-enhanced spectral mammography for breast cancer (MIB304)
NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)
NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .
NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .
Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy (MIB316)
NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy .
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)
NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)
NICE has developed a medtech innovation briefing (MIB) on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)
NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .